McKesson Boosts FY23 Outlook Backed By Strong Contribution From COVID-19 Drugs
McKesson Corp (NYSE: MCK ) reported Q1 FY23 adjusted EPS of $5.83 , 5% Y|Y, beating the consensus of $5.27. Revenues increased 7% Y|Y to $67.15 billion, surpassing the consensus of $65.14 billion. U.S. Pharmaceutical segment''s revenues were $56.9 billion, 14%, driven by an increased volume of specialty products, including higher volumes from retail national account customers, and market growth, partially offset by branded to generic … Full story available on Benzinga.com
McKesson Boosts FY23 Outlook Backed By Strong Contribution From COVID-19 Drugs
McKesson Corp (NYSE: MCK ) reported Q1 FY23 adjusted EPS of $5.83 , 5% Y|Y, beating the consensus of $5.27. Revenues increased 7% Y|Y to $67.15 billion, surpassing the consensus of $65.14 billion. U.S. Pharmaceutical segment''s revenues were $56.9 billion, 14%, driven by an increased volume of specialty products, including higher volumes from retail national account customers, and market growth, partially offset by branded to generic … Full story available on Benzinga.com